Straits Times Index
3,378.29 -15.92 (-0.47%) S&P 500
4,070.56 +10.13 (+0.25%) Dow
33,978.08 +28.68 (+0.08%) Nasdaq
11,621.71 +109.31 (+0.95%) BTC-USD
23,124.26 -298.46 (-1.27%) CMC Crypto 200
523.44 +6.43 (+1.24%)
PAVmed Inc. (PAVM)
After hours:
- Business Wire
PAVmed and Lucid Diagnostics Provide Strategic Business Update
NEW YORK, January 17, 2023--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiaries Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or "Lucid Diagnostics"), a commercial-stage cancer prevention diagnostics company, and Veris Health Inc. ("Veris"), a private digital health company focused on enhanced personalized cancer care, today provided a
- Business Wire
PAVmed and Lucid Diagnostics to Provide Strategic Business Update
NEW YORK, January 11, 2023--Companies will present refinements to their business strategy as each continue to the benefit patients in need and create value for shareholders.
- Business Wire
PAVmed Partners with Novosound on Ultrasound Imaging Technology
NEW YORK, December 22, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has entered into a license option and joint research and development agreement with Novosound Ltd. ("Novosound"), a venture-backed technology company based in Glasgow, Scotland, to explore applying Novosound’s proprietary flexible thin-film ultrasound technology in me
